Genetic aspects of Sjögren's syndrome

ar599 ARJ Review Genetic aspects of Sjögren's syndrome Bolstad Isine Anne anne.bolstad@gades.uib.no Jonsson Roland

Broegelmann Research Laboratory, Department of Microbiology and Immunology, The Gade Institute, University of Bergen, Bergen, Norway

Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

Arthritis Res 1465-9905 2002 4 6 353 359 10.1186/ar599 12453311 1 7 2002 23 8 2002 28 8 2002 24 9 2002 2002 BioMed Central Ltd apoptosis autoimmune disease candidate genes cytokines HLA

Abstract

Sjögren's syndrome is a multisystem inflammatory rheumatic disease that is classified into primary and secondary forms, with cardinal features in the eye (keratoconjunctivitis sicca) and mouth (xerostomia). The aetiology behind this autoimmune exocrinopathy is probably multifactorial and influenced by genetic as well as by environmental factors that are as yet unknown. A genetic predisposition to Sjögren's syndrome has been suggested on the basis of familial aggregation, animal models and candidate gene association studies. Recent advances in molecular and genetic methodologies should further our understanding of this complex disease. The present review synthesizes the current state of genetics in Sjögren's syndrome.

Introduction

Sjögren's syndrome is an autoimmune exocrinopathy of unknown aetiology. It is a member of the group of inflammatory rheumatic disorders classified as connective tissue diseases. Clinical experience indicates not only an overlap among these disorders but also a close relationship of, for example, autoantibody profiles 1. The genetic implications of this overlap has not been extensively explored, and the genetics behind Sjögren's syndrome per se are not well characterized.

There is no single disease-specific diagnostic criterion for Sjögren's syndrome. For diagnosis, the most functional criteria are the recently modified European classification criteria, which include a list of exclusions 2. In addition to the subjective symptoms of dry eyes and dry mouth, the following objective signs should be present: ocular signs by Schirmer's I test and/or Rose Bengal score; focal sialadenitis by histopathology; salivary gland involvement by either salivary scintigraphy, parotid sialography or unstimulated salivary flow; and autoantibodies of Ro/ Sjögren syndrome antigen A (SSA) and/or La/Sjögren syndrome antigen B (SSB) specificity.

Sjögren's syndrome occurs worldwide and in all ages. However, the peak incidence is in the fourth and fifth decades of life, with a female:male ratio of 9:1. A number of studies have shown great variation in the frequency of Sjögren's syndrome (for review 3). Prevalence studies have demonstrated that sicca symptoms and primary Sjögren's syndrome affects a considerable percentage of the population, with precise numbers dependent on the age group studied and on the criteria used 4. A cautious but realistic estimate from the studies presented thus far is that primary Sjögren's syndrome is a disease with a prevalence not exceeding 0.6% of the general population (6/1000).

Although generally considered a T-cell-mediated disease, potential mechanisms underlying Sjögren's syndrome range from disturbances in apoptosis 56 to circulating autoantibodies against the ribonucleoproteins Ro and La 78 or cholinergic muscarinic receptors 91011 in salivary and lacrimal glands in genetically predisposed individuals. Others relate reduced salivary and tear flow to aberrant glandular aquaporin-5 water channel proteins 121314, although this is not unambiguous 15. Possibly of greater importance is the recently described selective downregulation of aquaporin-1 expression in myoepithelial cells in salivary glands in primary Sjögren's syndrome 16.

Genetic predisposition to Sjögren's syndrome

A genetic predisposition to Sjögren's syndrome appears to exist, and several families involving two or more cases of Sjögren's syndrome have been described 17181920212223. However, the level of genetic contribution is not known. Because large twin studies in Sjögren's syndrome are lacking, the twin concordance rate cannot be estimated. Only a few case reports describing twins with primary Sjögren's syndrome are available 24252627. Twins exhibited a very similar phenotype with almost identical clinical presentation, including dry eyes and dry mouth; similar serological data (IgG, IgM, IgA, C3, C4, antinuclear antibody, anti-Ro/SSA and anti-La/SSB, rheumatoid factor), with identical fine specificity in their immune responses to 60kDa Ro/SSA; and identical labial salivary gland focus scores 2427.

Familial clustering of different autoimmune diseases and co-association of multiple autoimmune diseases in individuals have frequently been reported 28. Interestingly, it is common for a Sjögren's syndrome proband to have relatives with other autoimmune diseases (approximately 30–35%) 172930. Furthermore, Sjögren's syndrome exists in two forms – primary and secondary; the form that is present depends on whether it occurs alone or together with other connective diseases, such as systemic lupus erythematosus or rheumatoid arthritis 31. Clustering of non-major histocompatibility complex (MHC) susceptibility candidate loci in human autoimmune diseases supports a hypothesis that, in some cases, clinically distinct autoimmune diseases may be controlled by a common set of susceptibility genes 32.

Sjögren's syndrome is considered a complex disorder. Susceptibility to the disease can be ascribed to an interplay between genetic factors and the environment. In complex diseases, one specific gene is neither necessary nor sufficient for disease expression. This makes the genetics behind these diseases more complicated than those of diseases with a simple Mendelian character.

Sjögren's syndrome is major histocompatility complex associated

The polymorphic MHC genes are the best documented genetic risk factors for the development of autoimmune diseases overall 333435. With regard to Sjögren's syndrome, the most relevant MHC complex genes are the class II genes, specifically the human leukocyte antigen (HLA)-DR and HLA-DQ alleles 36. Patients of different ethnic origins exhibit different HLA gene associations 37. In Caucasians of northern and western European backgrounds, including North American Caucasians, Sjögren's syndrome is among several autoimmune diseases that are associated with the haplotypes B8, DRw52 and DR3. The increased frequency of HLA-B8 was presumably due to an association with the HLA class II allele HLA-DRB1*03. However, a novel association of HLA class I alleles (i.e. HLA-A24) to susceptibility to primary Sjögren's syndrome was recently reported 38. Beyond that, an association with DR2 has been found in Scandinavians 39 and with DR5 in Greeks 40. All of the haplotypes are in strong linkage disequilibrium, resulting in certain difficulties in establishing which of the genes contains the locus that confers the risk. DQCAR is a very polymorphic CA repeat microsatellite located between the HLA DQA1 and DQB1 gene and specific DQCAR alleles have been found to be in tight linkage disequilibrium with known HLA DR-DQ haplotypes. HLA-DQB1 CAR1/CAR2 allele frequencies were found to be significantly different in patients with Sjögren's syndrome as compared with healthy control individuals in a study in which the Kaplan criteria were used to classify Sjögren's syndrome 41.

Apparently, the HLA haplotype may influence the severity of autoimmune disease. It has been claimed that Sjögren's syndrome patients with DQ1/DQ2 alleles have a more severe autoimmune disease than do patients with any other allelic combination at HLA-DQ 42, and the DR3-DQ2 haplotype has been indicated as a possible marker for a more active immune response in Finnish patients with Sjögren's disease 43.

HLA is associated with the presence of Ro and La autoantibodies in Sjögren's syndrome

Distinct HLA haplotypes have been associated with certain degrees of autoantibody diversification in Sjögren's syndrome 44. Autoantibodies to Ro/SSA and La/SSB have been found to be associated with DR3, DQA and DQB alleles 454647. A dose-dependent contribution of DQα-34Q and DQβ-26L, in addition to the DRB1*03-DQB1*02-DQA1*0501 haplotype encompassing the transethnically associated DQβ-DI motif, represented the strongest contributors to the formation of an anti-Ro/La response in Norwegian patients with Sjögren's syndrome 45. A stronger correlation has been found between anti-Ro/SSA autoantibodies and DR3/DR2 than that with the disease itself 45484950. In Japanese persons, HLA class II allele association has been reported to differ among anti-Ro/SSA-positive individuals according to the presence or absence of coexisting anti-La/SSB 51.

Cytokine polymorphisms in Sjögren's syndrome

Cytokines serve to mediate and regulate immune and inflammatory responses, and have been implicated in the pathogenesis of a variety of autoimmune diseases, including Sjögren's syndrome. Numerous investigators have attempted to analyze the association of primary Sjögren's syndrome with cytokine polymorphisms, but at present no convincing relationship has been identified (for review 52).

Both human and animal studies indicate the involvement of IL-10 in the pathogenesis of primary Sjögren's syndrome 53 and mice transgenic for IL-10 develop a Fas-ligand-mediated exocrinopathy that resembles Sjögren's syndrome 54. A recent study described an association between primary Sjögren's syndrome and IL-10 promoter polymorphisms in a cohort of Finnish individuals, and a specific haplotype was found to correlate with high plasma levels of IL-10 55. Conversely, no association was found for IL-10 promoter polymorphism and primary Sjögren's syndrome or the presence of Ro autoantibodies in an Australian cohort of primary Sjögren's syndrome patients 56.

The IL-1 receptor antagonist regulates IL-1 activity in inflammatory disorders by binding to IL-1 receptors and thus inhibiting the activity of IL-1. The human IL-1 receptor antagonist gene (i.e. IL1RN) has a variable allelic polymorphism within intron 2 as a result of variation in number of an 86-base-pair sequence repeat 52. An increased frequency and carriage rate of the IL1RN*2 allele has been found in primary Sjögren's syndrome 57. No statistically significant association can be ascribed to tumour necrosis factor-α and primary Sjögren's syndrome 58.

Additional candidate gene studies

Because there is no disease-specific criterion for Sjögren's syndrome, the candidate genes studied may be related to other autoimmune phenotypes also. Mutations in the apoptosis genes have been identified as a possible cause or a contributing factor to human diseases 59, and the role of apoptosis has also been a major topic in autoimmune diseases, including primary Sjögren's syndrome (for review 56).

An increased frequency of apoptosis in ductal epithelial cells of the salivary glands leading to reduced salivary flow has been proposed as a possible disease mechanism 6061. Other investigators have suggested that inflammatory mononuclear cells are able to escape apoptosis because of defects in the death signalling pathway, which lead to accumulation of lymphocytes to displacement of functioning acinar cells 662. In the complex cascade of apoptotic signal molecules, Fas and Fas ligand are central actors. An insert of a retrotransposon in the Fas gene was discovered in the murine model MRL/lpr-lpr, which exhibits progressive focal sialadenitis, and has as such been forwarded as a possible explanation for aberrant apoptosis in that experimental model 63646566. This finding led to speculation over whether a similar phenomenon may be present in the human Fas gene. Now, more than 20 distinct Fas mutations are known in humans, and mutations in this gene have been identified as cause of or factor contributing to human diseases, such as autoimmune lymphoproliferative syndrome type I (for review 59). Polymorphisms in the Fas and FasL genes have also been found in primary Sjögren's syndrome 67. However, none of the polymorphisms in Fas or FasL entailed amino acid changes in patients with primary Sjögren's syndrome, and at present there exists no clear-cut mutation or defect in these genes that is clearly associated with primary Sjögren's syndrome and as such can be regarded as a disease-determining factor. Notably, the apoptosis cascade is built up of a huge number of signal molecules, and the possibility that there should be polymorphisms or mutations of vital importance for development of the disease among these factors still exists. Thus far, however, a definite role for apoptosis in primary Sjögren's syndrome cannot be confirmed.

The contribution of Ro/SSA and La/SSB in Sjögren's syndrome is not fully understood. It is not known how tolerance breakdown and autoantibody response to Ro/SSA and La/SSB is generated. The ribonucleoproteins are endogenous proteins that are normally hidden from the immune system, and should subsequently not give rise to abnormal B-cell responses. However, stress such as ultraviolet radiation, viral infections and apoptosis have been suggested to lead to undesirable cell surface exposure of autoantigens to the immune system 7. Ro/SSA and La/SSB have been demonstrated in surface blebs of apoptotic ultraviolet-irradiated keratinocytes, implying a role in systemic lupus erythematosus 68. Not much is known from a genetic point of view, but an association study has been performed in Ro5269. A single nucleotide polymorphism in intron 3 of the Ro52 gene was found to be strongly associated with the presence of anti-Ro52 autoantibodies in primary Sjögren's syndrome 69. This is interesting because alternative mRNA is made by deleting exon 4, which encodes a putative leucine zipper domain, to generate a shorter version of the Ro52 protein 70.

Genes that encode transporters associated with antigen processing (i.e. TAP genes) have also been associated with susceptibility to Sjögren's syndrome 71. Others have indicated a putative role for the cysteine-rich secretory protein 3 (CRISP-3) gene as an early response gene that may participate in the pathophysiology of the autoimmune lesions of Sjögren's syndrome 72.

A 44-fold increased risk for the development of B-cell lymphoma has been documented in Sjögren's syndrome, and a role for activated B cells has been implicated 73. Notably, it is not known whether B-cell activation is a primary cause or a secondary manifestation in Sjögren's syndrome. Patients are known to have increased levels of serum IgG 3. Although the cellular basis of this hypergammaglobulinaemia and the strong associations of certain autoantibodies with particular MHC class II molecules have been intensively examined, little is known about the usage of IgV (immunoglobulin variable) region genes, and especially by autoantibodies in autoimmune diseases. Therefore, a study of IgVλ light chain gene usage in primary Sjögren's syndrome patients was undertaken by Kaschner et al. 74. Those investigators identified molecular differences from controls in V-J recombination and concluded that disturbed regulation of B-cell maturation with abnormal selection, defects in editing immunoglobulin receptors and abnormal mutational targeting may contribute to the emergence of autoimmunity in Sjögren's syndrome.

Rheumatoid factors are autoantibodies against antigenic determinants that are present on the Fc portion of human IgG, and are found in sera and saliva of 60–80% of patients with primary Sjögren's syndrome 3. We found rheumatoid factor to be present in sera of 91% of Norwegian anti-Ro-positive patients with primary Sjögren's syndrome 45. The genetic origin and the mechanisms underlying its generation have been investigated in primary Sjögren's syndrome 75. In such patients, rheumatoid factor used diverse V_H region genes, the majority of which show no evidence of somatic hypermutation, whereas light chain variable (V_L) sequences exhibited a moderate contribution of somatic hypermutation 76.

Understanding primary Sjögren's syndrome in view of animal models

An appropriate animal model of Sjögren's syndrome could greatly advance our ability to identify the target antigens, characterize the immune mechanisms and define the genetic background. Several animal models, both experimentally induced and spontaneous inflammatory reactions with features of human Sjögren's syndrome, have been reported and previously reviewed 77.

The nonobese diabetic (NOD) mouse develops a disease that mimicks human type 1 diabetes mellitus and has been intensively studied for this phenotype. It also spontaneously develops sialadenitis and several other features of Sjögren's syndrome, including autoantibodies against Ro/SSA 77. The NOD mouse carries the MHC H2^g7 haplotype. In order to study the importance of NOD non-MHC genes, an H2^q congenic NOD mouse, namely NOD.Q, was established 7879. Recently, a gene segregation experiment was conducted in a (NOD.Q × B10.Q)F₂ cross, and genetic mapping revealed one locus (Nss1) associated with sialadenitis on chromosome 4 (LOD score 4.7; Fig. 1) 78. The H2^g7 haplotype was not critical for sialadenti-tis development in the NOD background because the NOD.Q mouse also developed sialadenitis. The genetic control of sialadenitis appeared to be unique in comparison with diabetes and arthritis, because no loci associated with these diseases have been identified at the same location 79. This supports earlier findings that the sicca syndrome occurs independently of autoimmune diabetes, and NOD MHC I-A^g7 was not essential for exocrine tissue autoimmunity 80.

Figure 1

Chromosomal map illustrating the location of identified quantitative trait loci associated with sialadenitis development in various murine models.

Chromosomal map illustrating the location of identified quantitative trait loci associated with sialadenitis development in various murine models. Chromosomal positions are based on the map from the Jackson Laboratory http://informatics.jax.org/. Sialadenitis susceptibility loci are drawn from *78, ^¶82, ^†83 and ^‡84; markers with LOD score >3.3 are underscored, however, for the markers Il2, Asm2 and Hsp70 a LOD score >3.3 was only obtained in females and for the marker D1Mit153 only in males.

More recently, alleles from chromosomes 1 and 3 of NOD mice have been found to combine to influence Sjögren's syndrome-like autoimmune exocrinopathy 81, and two intervals contribute synergistically to the development of Sjögren's syndrome on a healthy murine background; this has also been demonstrated in the NOD mouse after crossing (Fig. 1) 82. Very recently, chromosome 1 was reported to be a major susceptibility region for development of autoimmune sialadenitis 83. In different matings of NOD mice, including a (NOD × C57BL/6 [B6])F₂ cross, a (NOD × NZW)F₂ cross, and a ([NOD × B6] × NOD) backcross, an association with the middle region of chromosome 1 was detected in all crosses.

The NZB, MRL/lpr, NOD and NFS/sld strains are all experimental murine models that spontaneously develop salivary gland inflammation, of which the MRL/lpr and the NOD strains present with serum anti-Ro/SSA antibodies. An insertion of an ET-transposon in the Fas gene has been found to be responsible for the lpr genotype in the MRL/lpr mouse 65. Similar Fas gene insertions could not be traced in Sjögren's syndrome patients 67. A genome-wide scan of MRL/lpr mice revealed four susceptible loci, mapped on chrosome 10, 18, 4 and 1, which were recessively associated with sialadenitis 84. The sialadenitis in MRL/lpr mice is probably under the control of polygenic inheritance, because the loci manifested an additive effect in a hierarchical manner. The different susceptibility loci reported for sialadenitis are outlined in Fig. 1.

Transgenic mice have frequently been used as models to study the role of viruses in the pathogenesis of a variety of diseases and to determine the importance of cytokines such as IL-10 54. Transgenic expression of IL-10 induced apoptosis of glandular tissue and promoted infiltration of lymphocytes. Transgenic mice containing the human T-cell lymphotropic virus type-1 tax gene under the control of the viral long terminal repeat (LTR) develop an exocrinopathy that involves the salivary and lacrimal glands, resembling the pathology of Sjögren's syndrome 85. It was suggested that human T-cell lymphotropic virus type-1 may represent a primary event in the development of exocrinopathy by virally induced proliferation and perturbation of the function of ductal epithelium. Sialadenitis and inflammation in lachrymal glands histologically resembling Sjögren's syndrome have also been found in mice transgenic for hepatitis C virus envelope genes 86.

Conclusion

Very little is known about the genetics of Sjögren's syndrome. Although not conclusive, however, recent findings in animal breeding studies are promising with respect to resolving issues in Sjögren's syndrome. Of special interest were the major susceptibility loci for autoimmune sialadenitis demonstrated on chromosomes 1, 4 and 10 in murine models. For instance, the chromosomal regions around Nss1 on chromosome 4 harbour a set of genes that are probably of importance for different kinds of autoimmune syndromes, because several loci associated with autoimmune disease models for systemic lupus erythematosus and autoimmune haemolytic anaemia are clustered around Nss1 (for review 78). Interestingly, no association between sialadenitis in the NOD.Q and collagen-induced arthritis was observed 78.

Human linkage studies of Sjögren's syndrome families, in addition to analyses of gene expression signatures on microarrays, will probably be an important source of information in the future. Identification of new genetic markers may lead to development of better diagnostic and prognostic tests in Sjögren's syndrome, including its systemic complications. However, as with the other rheumatic diseases, it is anticipated that both overlap and discrepancies will be detected during genome screens. Given the likely heterogeneity of Sjögren's syndrome, advances will probably not be made without future global collaboration.

Abbreviations

HLA = human leukocyte antigen; IL = interleukin; LTR = long terminal repeat; MHC = major histocompatibility complex; NOD = nonobese diabetic; SSA = Sjögren syndrome antigen A; SSB = Sjögren syndrome antigen B.

Acknowledgements

Studies by the authors were financed with the aid of EXTRA funds from the Norwegian Foundation for Health and Rehabilitation, the European BIOMED program (BMH4-CT98-3489) and the Broegelmann Foundation.

Sjögren's syndrome. Jonsson R Brokstad KA In Samter's Immunologic Diseases Philadelphia: Lippincott, Williams & Wilkins Austen KF, Frank MM, Atkinson JP, Cantor H 6 2001 495 504 Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Vitali C Bombardieri S Jonsson R Moutsopoulos HM Alexander EL Carsons SE Daniels TE Fox PC Fox RI Kassan SS Pillemer SR Talal N Weisman MH Ann Rheum Dis 2002 61 554 558 10.1136/ard.61.6.554 12006334 <it>Sjögren's</it> syndrome. Jonsson R Haga H-J Gordon T In: Arthritis and Allied Contitions: a Textbook of Rheumatology Philadelphia: Lippincott, Williams & Wilkins, Koopman WJ 14 2001 1736 1759 Epidemiology of Sjögren's syndrome. Silman AJ Rooney BK In The 100-year Anniversary of Henrik Sjögren. Jönköping: Hygiea, Eriksson E, Jonsson R 1999 53 57 The role of apoptosis in Sjögren's syndrome. Bolstad AI Jonsson R Ann Med Interne 1998 149 25 29 Fas-induced apoptosis is a rare event in Sjögren's syndrome. Ohlsson M Skarstein K Bolstad AI Johannessen AC Jonsson R Lab Invest 2001 81 95 105 11204278 Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigen during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Ohlsson M Jonsson R Brokstad K Scand J Immunol 2002 Autoantibodies in primary Sjögren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Gordon TP Bolstad AI Rischmueller M Jonsson R Waterman SA Autoimmunity 2001 34 123 132 11905842 Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjögren's syndrome. Beroukas D Goodfellow R Hiscock J Jonsson R Gordon TP Waterman SA Lab Invest 2002 82 203 210 11850533 Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Bacman S Sterin-Borda L Camusso JJ Arana R Hubscher O Borda E Clin Exp Immunol 1996 104 454 459 10.1046/j.1365-2249.1996.42748.x 9099930 An alternative perspective to the immune response in autoimmune exocrinopathy: induction of functional quiescence rather than destructive autoaggression. Humphreys-Beher MG Brayer J Yamachika S Peck AB Jonsson R Scand J Immunol 1999 49 7 10 10.1046/j.1365-3083.1999.00490.x 10023850 Defective secretion of saliva in transgenic mice lacking aquaporin-5 water channels. Ma T Song Y Gillespie A Carlson EJ Epstein CJ Verkman AS J Biol Chem 1999 274 20071 20074 10.1074/jbc.274.29.20071 10400615 Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren's syndrome patients. Steinfeld S Cogan E King LS Agre P Kiss R Delporte C Lab Invest 2001 81 143 148 11232635 Defective cellular trafficking of lacrimal gland aquaporin-5 in Sjögren's syndrome. Tsubota K Hirai S King LS Agre P Ishida N Lancet 2001 357 688 689 10.1016/S0140-6736(00)04140-4 11247557 Subcellular distribution of aquaporin 5 in salivary glands in primary Sjögren's syndrome. Beroukas D Hiscock J Jonsson R Waterman SA Gordon TP Lancet 2001 358 1875 1876 10.1016/S0140-6736(01)06900-8 11741631 Selective downregulation of aquaporin-1 in salivary glands in primary Sjögren's syndrome. Beroukas D Hiscock J Gannon BJ Jonsson R Gordon TP Waterman SA Lab Invest 2002 Primary Sjögren's syndrome and other autoimmune diseases in families. Prevalence and immunogenetic studies in six kindreds. Reveille JD Wilson RW Provost TT Bias WB Arnett FC Ann Intern Med 1984 101 748 756 6437309 Familial Sjögren's syndrome with associated primary salivary gland lymphoma. Lichtenfeld JL Kirschner RH Wiernik PH Am J Med 1976 60 286 292 766625 Familiar characteristics of Sjögren's disease. (Clinical contribution and considerations) [in Italian]. Doni A Brancato R Bartoletti L Berni G Riv Crit Clin Med 1965 65 750 759 5870233 Sjögren's syndrome and achalasia of the cardia in two siblings. Koivukangas T Simila S Heikkinen E Rasanen O Wasz-Hockert O Pediatrics 1973 51 943 945 4703408 Multiple immunological abnormalities in a family. Mason AM Golding PL J Clin Pathol 1971 24 732 735 5316137 Primary Sjögren's syndrome and autoimmune hemolytic anemia in sisters. A family study. Boling EP Wen J Reveille JD Bias WB Chused TM Arnett FC Am J Med 1983 74 1066 1071 6859056 A multicase family with primary Sjögren's syndrome. Sabio JM Milla E Jimenez-Alonso J J Rheumatol 2001 28 1932 1934 11508606 Immunologically restricted and inhibitory anti-Ro/SSA in monozygotic twins. Scofield RH Kurien BT Reichlin M Lupus 1997 6 395 398 9175026 Chronic bilateral dacryo-adenitis in identical twins: a possible incomplete form of Sjögren syndrome. Besana C Salmaggi C Pellegrino C Pierro L Vergani S Faravelli A Rugarli C Eur J Pediatr 1991 150 652 655 1915519 Identical twins of Sjorgren's syndrome with renal tubular acidosis (author's transl) [in Japanese]. Koga T Ebata H Tanigawa K Yamagata Y Nippon Naika Gakkai Zasshi 1980 69 1458 1462 7195418 Monozygotic twins with primary Sjögren's syndrome. Bolstad AI Haga HJ Wassmuth R Jonsson R J Rheumatol 2000 27 2264 2266 10990245 Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Becker KG Simon RM Bailey-Wilson JE Freidlin B Biddison WE McFarland HF Trent JM Proc Natl Acad Sci USA 1998 95 9979 9984 21447 9707586 10.1073/pnas.95.17.9979 The occurrence of various collagen diseases in one family: a sister with ISSc, PBC, APS, and SS and a brother with systemic lupus erythematosus. Tanaka A Igarashi M Kakinuma M Oh-i T Koga M Okuda T J Dermatol 2001 28 547 553 11732722 The immunogenetics of Sjögren's syndrome. Reveille JD Arnett FC Rheum Dis Clin North Am 1992 18 539 550 1496160 Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome. Jonsson R Haga HJ Gordon TP Scand J Rheumatol 2000 29 341 348 10.1080/030097400447525 11132201 Genetic susceptibility to the development of autoimmune disease. Heward J Gough SC Clin Sci (Lond) 1997 93 479 491 9497784 MHC and autoimmune diseases. Nepom GT Immunol Ser 1993 59 143 164 8461386 Genetics of autoimmune disease. Merriman TR Todd JA Curr Opin Immunol 1995 7 786 792 10.1016/0952-7915(95)80049-2 8679121 The HLA system and the analysis of multifactorial genetic disease. Tomlinson IP Bodmer WF Trends Genet 1995 11 493 498 10.1016/S0168-9525(00)89159-3 8533166 The molecular genetics of systemic lupus erythematosus and Sjögren's syndrome. Reveille JD Curr Opin Rheumatol 1992 4 644 656 1419498 Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjögren's syndrome. Kang HI Fei HM Saito I Sawada S Chen SL Yi D Chan E Peebles C Bugawan TL Erlich HA J Immunol 1993 150 3615 3623 8468491 HLA class I and class II are both associated with the genetic predisposition to primary Sjögren syndrome. Loiseau P Lepage V Djelal F Busson M Tamouza R Raffoux C Menkes CJ Meyer O Charron D Goldberg D Hum Immunol 2001 62 725 731 10.1016/S0198-8859(01)00253-1 11423179 HLA-D antigen frequencies in Sjögren's syndrome. Differences between the primary and secondary form. Manthorpe R Morling N Platz P Ryder LP Svejgaard A Thomsen M Scand J Rheumatol 1981 10 124 128 6941466 HLA-alloantigen associations in Greek patients with Sjögren's syndrome. Papasteriades CA Skopouli FN Drosos AA Andonopoulos AP Moutsopoulos HM J Autoimmun 1988 1 85 90 3151145 Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome. Harley JB Reichlin M Arnett FC Alexander EL Bias WB Provost TT Science 1986 232 1145 1147 3458307 Distinct immunologic features of Finnish Sjögren's syndrome patients with HLA alleles DRB1* DQA1*0501, and DQB1*0201. Alterations in circulating T cell receptor gamma/delta subsets. Kerttula TO Collin P Polvi A Korpela M Partanen J Maki M Arthritis Rheum 0301 39 1733 1739 HLA-DQB1 CAR1/CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjögren's syndrome. Kacem HH Kaddour N Adyel FZ Bahloul Z Ayadi H Rheumatology (Oxford) 2001 40 1370 1374 10.1093/rheumatology/40.12.1370 11752507 HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS). Rischmueller M Lester S Chen Z Champion G Van Den Berg R Beer R Coates T McCluskey J Gordon T Clin Exp Immunol 1998 111 365 371 10.1046/j.1365-2249.1998.00504.x 9486405 HLA markers and clinical characteristics in Caucasians with primary Sjögren's syndrome. Bolstad AI Wassmuth R Haga HJ Jonsson R J Rheumatol 2001 28 1554 1562 11469461 Associations of MHC class II alleles in Norwegian primary Sjögren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen. Nakken B Jonsson R Brokstad KA Omholt K Nerland AH Haga HJ Halse AK Scand J Immunol 2001 54 428 433 10.1046/j.1365-3083.2001.00993.x 11555411 Specific HLA-DQA and HLA-DRB1 alleles confer susceptibility to Sjögren's syndrome and autoantibody production. Fei HM Kang H Scharf S Erlich H Peebles C Fox R J Clin Lab Anal 1991 5 382 391 1685512 Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sjögren's syndrome. Arnett FC Hamilton RG Reveille JD Bias WB Harley JB Reichlin M Arthritis Rheum 1989 32 413 419 2706027 Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Hamilton RG Harley JB Bias WB Roebber M Reichlin M Hochberg MC Arnett FC Arthritis Rheum 1988 31 496 505 2451920 Association of HLA-DR7 with both antibody to SSA(Ro) and disease susceptibility in blacks with systemic lupus erythematosus. Wilson WA Scopelitis E Michalski JP J Rheumatol 1984 11 653 657 6334744 Polymorphisms of HLA class II genes and autoimmune responses to Ro/SS-ALa/SS-B among Japanese subjects. Miyagawa S Shinohara K Nakajima M Kidoguchi K Fujita T Fukumoto T Yoshioka A Dohi K Shirai T Arthritis Rheum 1998 41 927 934 10.1002/1529-0131(199805)41:5<927::AID-ART21>3.0.CO;2-R 9588746 Cytokine polymorphisms in systemic lupus erythematosus and Sjögren's syndrome. Magnusson V Nakken B Bolstad AI Alarcon-Riquelme ME Scand J Immunol 2001 54 55 61 10.1046/j.1365-3083.2001.00965.x 11439148 Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Halse AK Tengner P Wahren-Herlenius M Haga H-J Jonsson R Scand J Immunol 1999 49 533 538 10.1046/j.1365-3083.1999.00533.x 10320647 Fas ligand-mediated exocrinopathy resembling Sjögren's syndrome in mice transgenic for IL-10. Saito I Haruta K Shimuta M Inoue H Sakurai H Yamada K Ishi-maru N Higashiyama H Sumida T Ishida H Suda T Noda T Hayashi Y Tsubota K J Immunol 1999 162 2488 2494 10072487 Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren's syndrome. Hulkkonen J Pertovaara M Antonen J Lahdenpohja N Pasternack A Hurme M Arthritis Rheum 2001 44 176 179 10.1002/1529-0131(200101)44:1<176::AID-ANR23>3.0.CO;2-K 11212157 Polymorphisms of the interleukin 10 gene promoter are not associated with anti-Ro autoantibodies in primary Sjögren's syndrome. Rischmueller M Limaye V Lester S Downie-Doyle S Pile K Bardy P Gordon TP J Rheumatol 2000 27 2945 2946 11128696 IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Perrier S Coussediere C Dubost JJ Albuisson E Sauvezie B Clin Immunol Immunopathol 1998 87 309 313 10.1006/clin.1998.4520 9646842 DRB1*15 and DRB1*03 extended haplotype interaction in primary Sjögren's syndrome genetic susceptibility. Jean S Quelvennec E Alizadeh M Guggenbuhl P Birebent B Perdriger A Grosbois B Pawlotsky PY Semana G Clin Exp Rheumatol 1998 16 725 728 9844767 Mutations in apoptosis genes: a pathogenetic factor for human disease. Mullauer L Gruber P Sebinger D Buch J Wohlfart S Chott A Mutat Res 2001 488 211 231 11397650 Quantitative analysis of apoptosis and bcl-2 in Sjögren's syndrome. Manganelli P Quaini F Andreoli AM Lagrasta C Pilato FP Zuc-carelli A Monteverdi R D'Aversa C Olivetti G J Rheumatol 1997 24 1552 1557 9263150 Glandular and extraglandular expression of the Fas-Fas ligand and apoptosis in patients with Sjögren's syndrome. Matsumura R Umemiya K Kagami M Tomioka H Tanabe E Sugiyama T Sueishi M Nakajima A Azuma M Okumura K Sumida T Clin Exp Rheumatol 1998 16 561 568 9779303 Lymphoid cell accumulation in salivary glands of autoimmune MRL mice can be due to impaired apoptosis. Skarstein K Nerland AH Eidsheim M Mountz JD Jonsson R Scand J Immunol 1997 46 373 378 10.1046/j.1365-3083.1997.d01-142.x 9350288 The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Mountz JD Zhou T Su X Wu J Cheng J Clin Immunol Immunopathol 1996 80 S2 S14 10.1006/clin.1996.0136 8811058 The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. Chu JL Drappa J Parnassa A Elkon KB J Exp Med 1993 178 723 730 7688033 Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. Wu J Zhou T He J Mountz JD J Exp Med 1993 178 461 468 7688023 Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Adachi M Watanabe-Fukunaga R Nagata S Proc Natl Acad Sci USA 1993 90 1756 1760 45958 7680478 Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome. Bolstad AI Wargelius A Nakken B Haga HJ Jonsson R J Rheumatol 2000 27 2397 2405 11036836 Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. Casciola-Rosen LA Anhalt G Rosen A J Exp Med 1994 179 1317 1330 7511686 Polymorphisms of the Ro52 gene associated with anti-Ro 52-kd autoantibodies in patients with primary Sjögren's syndrome. Nakken B Jonsson R Bolstad AI Arthritis Rheum 2001 44 638 646 10.1002/1529-0131(200103)44:3<638::AID-ANR112>3.3.CO;2-A 11263778 52-kD SS-A/Ro: genomic structure and identification of an alternatively spliced transcript encoding a novel leucine zipperminus autoantigen expressed in fetal and adult heart. Chan EK Di Donato F Hamel JC Tseng CE Buyon JP J Exp Med 1995 182 983 992 7561701 Association of a new allele of the TAP2 gene, TAP2*Bky2 (Val577), with susceptibility to Sjögren's syndrome. Kumagai S Kanagawa S Morinobu A Takada M Nakamura K Sugai S Maruya E Saji H Arthritis Rheum 1997 40 1685 1692 9324024 Characterization of the cysteine-rich secretory protein 3 gene as an early-transcribed gene with a putative role in the pathophysiology of Sjögren's syndrome. Tapinos NI Polihronis M Thyphronitis G Moutsopoulos HM Arthritis Rheum 2002 46 215 222 10.1002/1529-0131(200201)46:1<215::AID-ART10024>3.0.CO;2-M 11817594 Increased risk of lymphoma in sicca syndrome. Kassan SS Thomas TL Moutsopoulos HM Hoover R Kimberly RP Budman DR Costa J Decker JL Chused TM Ann Intern Med 1978 89 888 892 102228 Immunoglobulin Vlambda light chain gene usage in patients with Sjögren's syndrome. Kaschner S Hansen A Jacobi A Reiter K Monson NL Odendahl M Burmester GR Lipsky PE Dorner T Arthritis Rheum 2001 44 2620 2632 10.1002/1529-0131(200111)44:11<2620::AID-ART442>3.0.CO;2-M 11710718 Rheumatoid factors in primary Sjögren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation. Elagib KE Borretzen M Jonsson R Haga HJ Thoen J Thompson KM Natvig JB Clin Exp Immunol 1999 117 388 394 10.1046/j.1365-2249.1999.00963.x 10444275 Light chain variable (VL) sequences of rheumatoid factors (RF) in patients with primary Sjögren's syndrome (pSS): moderate contribution of somatic hypermutation. Elagib KE Borretzen M Thompson KM Natvig JB Scand J Immunol 1999 50 492 498 10.1046/j.1365-3083.1999.00624.x 10564552 Experimental models of Sjögren's Syndrome. Jonsson R Skarstein K In: The Molecular Pathology of Autoimmune Diseases New York: Taylor & Francis; Theofilopoulos AN, Bona CA 2 2002 437 452 The genetic control of sialadenitis versus arthritis in a NOD.QxB10.Q F2 cross. Johansson ACM Nakken B Sundler M Lindqvist AK Johannesson M Alarcon-Riquelme M Bolstad AI Humphreys-Beher MG Jonsson R Skarstein K Holmdahl R Eur J Immunol 2002 32 243 250 10.1002/1521-4141(200201)32:1<243::AID-IMMU243>3.0.CO;2-X 11782015 Genetic control of collagen-induced arthritis in a cross with NOD and C57BL/10 mice is dependent on gene regions encoding complement factor 5 and FcgammaRIIb and is not associated with loci controlling diabetes. Johansson AC Sundler M Kjellen P Johannesson M Cook A Lindqvist AK Nakken B Bolstad AI Jonsson R Alarcon-Riquelme M Holmdahl R Eur J Immunol 2001 31 1847 1856 10.1002/1521-4141(200106)31:6<1847::AID-IMMU1847>3.0.CO;2-F 11433381 A novel NOD-derived murine model of primary Sjögren's syndrome. Robinson CP Yamachika S Bounous DI Brayer J Jonsson R Holmdahl R Peck AB Humphreys-Beher MG Arthritis Rheum 1998 41 150 156 10.1002/1529-0131(199801)41:1<150::AID-ART18>3.3.CO;2-K 9433880 Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy. Brayer J Lowry J Cha S Robinson CP Yamachika S Peck AB Humphreys-Beher MG J Rheumatol 2000 27 1896 1904 10955330 Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjögren's syndrome) on a healthy murine backgrund. Cha S Nagashima H Brown VB Peck A Humphreys-Beher M Arthritis Rheum 2002 46 1390 1398 10.1002/art.10258 12115247 Genetic analysis of autoimmune sialadenitis in nonobese diabetic mice: a major susceptibility region on chromosome 1. Boulard O Fluteau G Eloy L Damotte D Bedossa P Garchon HJ J Immunol 2002 168 4192 4201 11937580 Genetic basis of autoimmune sialadenitis in MRL/lpr lupus-prone mice: additive and hierarchical properties of polygenic inheritance. Nishihara M Terada M Kamogawa J Ohashi Y Mori S Nakatsuru S Nakamura Y Nose M Arthritis Rheum 1999 42 2616 2623 10.1002/1529-0131(199912)42:12<2616::AID-ANR16>3.0.CO;2-O 10616009 Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice. Green JE Hinrichs SH Vogel J Jay G Nature 1989 341 72 74 10.1038/341072a0 2788824 Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes. Koike K Moriya K Ishibashi K Yotsuyanagi H Shintani Y Fujie H Kurokawa K Matsuura Y Miyamura T Proc Natl Acad Sci USA 1997 94 233 236 19297 8990191 10.1073/pnas.94.1.233